

Multilex Bulletin - December 2021

The Multilex Bulletin is an indication of notable changes made to the Multilex database. It also provides general information and advance warnings of changes for future months. Changes to product name are expressed in the form of the Multilex Preferred Display Name. Customers using other naming conventions may not see the changes as listed. Visibility of changes is dependent on the current data being loaded into your system and the specified element being available via your interface.

This document is not a list of all changes to the Multilex database.

The Multilex Bulletin is also available at www.fdbhealth.co.uk

Dm+d/Manufacturer Changes

The following products have been amended in line with the Dictionary of Medicines and Devices (dm+d) and/or the manufacturers' Summary of Product Characteristics (SPC):

Nebido 1g/4ml oily injection

Nebido 1g/4ml oily injection now reads:
Nebido 1g/4ml injection solution

Multilex generic
testosterone undecanoate 1g/4ml oily injection now reads:
testosterone undecanoate 1g/4ml injection solution

Drug Tariff Changes

The following products have been amended/updated in line with the December 2021 England and Wales Drug Tariff:

Aymes ActaJuce liquid

Aymes ActaJuce liquid (apple and orange flavours) now reads:
Aymes ActaGain Juce liquid (apple and orange flavours)

Aymes ActaJuce starter pack liquid now reads:
Aymes ActaGain Juce starter pack liquid

Senna 7.5mg/5ml oral solution sugar-free

Senna 7.5mg/5ml oral solution sugar-free now reads:
Sennoside 7.5mg/5ml oral solution sugar-free

Other Changes

Senna/Sennoside containing Products

In line with recommendations from the MHRA around the naming of senna and sennoside products, Multilex will be updating these records. This transition is expected to be gradual in line with information available from the dm+d and manufacturers.

It is possible during this transition that a sennoside product may link or connect to data labelled as senna, this is a minor naming issue and is expected to be resolved once all records are suitably aligned. In all

circumstances the suitability for the Clinical Decision Support displayed for the sennoside products will have been reviewed by the Clinical Content team before it is available to customers.